Novo Nordisk’s once-daily Wegovy® pill, the first FDA-approved oral GLP-1 therapy for weight loss in adults, is now broadly accessible across the U.S. Not only is it stocked at more than 70,000 retail pharmacies, but it’s also available through Amazon Pharmacy and leading telehealth platforms such as Ro, GoodRx, and WeightWatchers. This expansion follows the FDA approval on December 22, 2025, and marks a major milestone in obesity care.

Key Facts:

• Distribution Channels: In addition to CVS, Costco, and NovoCare Pharmacy, patients can now order Wegovy pills through Amazon Pharmacy for home delivery and via telehealth providers like Ro, which offers virtual consultations and prescription fulfillment.
• Pricing: Self-pay starts at $149/month for the 1.5 mg starter dose; higher doses will range up to $299/month. Insured patients may pay as little as $25/month.
• Clinical Data: Supported by the OASIS 4 Phase III trial, patients lost an average of 13.6% body weight, with higher adherence yielding up to 17% loss.
• Administration: Taken on an empty stomach with water; patients must wait 30 minutes before eating or drinking.

The oral medication responds to consumer demand for convenient, non-invasive medical weight loss solutions. With oral GLP-1 options reducing barriers for needle-averse patients, med spas can differentiate by providing holistic care: weight-loss medication plus aesthetic enhancements. Telehealth partnerships may also offer new revenue streams.

Offering GLP-1 medications requires strict adherence to state prescribing laws and medical supervision. Practices must ensure proper patient screening, informed consent, and monitoring for side effects such as nausea or vomiting. Speak with your medical director about adding prescription GLP-1 to your med spa’s offerings.

Learn more about building a medical weight loss program in your medical spa with clinical guidance from Taylor Siemens, NP in AmSpa Masters: Medical Weight Loss.